The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 07, 2025

Filed:

Nov. 20, 2023
Applicant:

Jjr&d, Llc, Celina, TN (US);

Inventors:

Joaquin J. Jimenez, Miami, FL (US);

John P. Mccook, Frisco, TX (US);

Assignee:

JJR&D, LLC, Celina, TN (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/15 (2025.01); A61K 9/00 (2006.01); A61K 40/17 (2025.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C12N 5/0786 (2010.01); C12N 5/0787 (2010.01);
U.S. Cl.
CPC ...
A61K 35/15 (2013.01); A61K 9/0019 (2013.01); A61K 40/17 (2025.01); A61P 35/02 (2018.01); C12N 5/0642 (2013.01); C12N 5/0645 (2013.01); A61K 2239/38 (2023.05);
Abstract

Compositions and methods for treating cancer, particularly leukemia, using a cytotoxic composition comprising monocytes activated by β-glucan. The monocytes are preferably incubated with the β-glucan and then processed to extract particles, such as microvesicles and exosomes from the treated monocytes to produce the cytotoxic composition. Preferably the cytotoxic composition comprises at least 50% exosomes having a size of 150 nm or less that are activated with β-glucan. Zymosan is the preferred β-glucan. The cytotoxic composition has an apoptosis effect. When a subject having cancer is treated according to preferred embodiments, the cytotoxic composition preferably induces a cytokine response in the subject's immune system. The combination of the cytotoxic composition and cytokine response are synergistic.


Find Patent Forward Citations

Loading…